Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8333 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.8323 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8302 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.828 |
Intermediate Similarity |
NPD3226 |
Approved |
0.8278 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.8258 |
Intermediate Similarity |
NPD2533 |
Approved |
0.8258 |
Intermediate Similarity |
NPD2534 |
Approved |
0.8258 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8258 |
Intermediate Similarity |
NPD2532 |
Approved |
0.8235 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.8221 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8187 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8158 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8158 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8148 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8133 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8118 |
Intermediate Similarity |
NPD8313 |
Approved |
0.8118 |
Intermediate Similarity |
NPD8312 |
Approved |
0.8105 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8105 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8084 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8061 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.8036 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8026 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8024 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.8012 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7988 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7962 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7929 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7914 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7908 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7908 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7898 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7888 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7882 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7866 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7862 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7857 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7853 |
Intermediate Similarity |
NPD2801 |
Approved |
0.784 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7836 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7824 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7821 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7818 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7805 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7799 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7791 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7778 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7758 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7748 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7746 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7746 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7744 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7742 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7716 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7711 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7702 |
Intermediate Similarity |
NPD920 |
Approved |
0.7683 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7682 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7677 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7658 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7651 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7647 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7633 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7633 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7628 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7628 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7625 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7619 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7619 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7596 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7593 |
Intermediate Similarity |
NPD5403 |
Approved |
0.759 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7578 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7576 |
Intermediate Similarity |
NPD37 |
Approved |
0.7545 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7545 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7545 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD411 |
Approved |
0.7514 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7484 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7484 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7484 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7473 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7473 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7473 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7473 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.7457 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7456 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7453 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD9717 |
Approved |
0.744 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7438 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7433 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7433 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7429 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7414 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7403 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7383 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7368 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7362 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7358 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7358 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7356 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7353 |
Intermediate Similarity |
NPD919 |
Approved |
0.7351 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7345 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7342 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7333 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7326 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7322 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7322 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7316 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7308 |
Intermediate Similarity |
NPD943 |
Approved |
0.7296 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7296 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7296 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7296 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7292 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.729 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.729 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7267 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.725 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.724 |
Intermediate Similarity |
NPD7874 |
Approved |
0.724 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7232 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7215 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7204 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7204 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7202 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7197 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7197 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7188 |
Intermediate Similarity |
NPD4476 |
Approved |
0.7188 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7186 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7182 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7179 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7178 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7174 |
Intermediate Similarity |
NPD6212 |
Phase 3 |
0.7174 |
Intermediate Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD6213 |
Phase 3 |
0.7171 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7161 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7159 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7152 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7152 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD17 |
Approved |
0.7125 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7118 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7117 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7114 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7108 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7101 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7089 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7089 |
Intermediate Similarity |
NPD4307 |
Phase 2 |
0.7089 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7086 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7076 |
Intermediate Similarity |
NPD4288 |
Approved |
0.707 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7068 |
Intermediate Similarity |
NPD8319 |
Approved |
0.7068 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7066 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD6844 |
Discontinued |
0.7055 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7051
|
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |